Tofacitinib (CP-690550)

For research use only.

Licensed by Pfizer Catalog No.S2789 Synonyms: Tasocitinib

119 publications

Tofacitinib (CP-690550) Chemical Structure

CAS No. 477600-75-2

Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) CAD 114 In stock
CAD 88 In stock
CAD 113 In stock
CAD 340 In stock
CAD 466 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Tofacitinib (CP-690550) has been cited by 119 publications

Purity & Quality Control

Choose Selective JAK Inhibitors

Biological Activity

Description Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
Targets
JAK3 [1]
(Cell-free assay)
JAK2 [1]
(Cell-free assay)
JAK1 [1]
(Cell-free assay)
1 nM 20 nM 112 nM
In vitro

CP-690550 is a specific, orally inhibitor of JAK3, it is 20- to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. [1] CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM). [2] CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. [3] A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cells MYHGeY5kfGmxbjDBd5NigQ>? MlXTNE4yNzBwMz:xJO69VQ>? NVG1S4FoOjRiaB?= NXvYO|BD\Gm|coXweJMh|rOlLXPoZYlvKGO7dH;rbY5mKHOrZ37hcIlv\w>? NVHqNVhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPFMzPDFpPkKxN|g{OjRzPD;hQi=>
CD4+ T  NUnMWpp4TnWwY4Tpc44hSXO|YYm= NHrBXokyODBibl2= MYmyOE81QCCq NWrMVIt5[WK{b3fheIV{KEOGMz3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVew>? M17QO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi0OVgxLz5{MUi4OFU5ODxxYU6=
CD4+ T  NHHHZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i3TVExOC93MECgcm0> NFP1Rmg1QCCq M{DkdIlvcGmkaYTzJIFvfGlvQ1SzMYlv\HWlZXSgR2Q1M8LiVDDj[YxtKHC{b3zp[oVz[XSrb36= MmDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6OES1PFAoRjJzOEi0OVgxRC:jPh?=
CD4+ T  NY[5SFNDTnWwY4Tpc44hSXO|YYm= Mk[wNlAwOTByL{WwNEBvVQ>? NEjFd2U1QCCq MnjXbY5pcWKrdIOgeIhmKGyndnXsd{Bw\iBiSVytOEwhUU[QLd8zMEBKVC1zN1GgZY5lKEmOLUKy NVPkTm0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFQ2QDBpPkKxPFg1PThyPD;hQi=>
Sf9 MmLDSpVv[3Srb36gZZN{[Xl? NXXTZYtnOzBibXnudy=> MVXJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC2odYPl[EBLSUt|IHPheIFtgXSrYzDkc41icW5iZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoOTDj[YxteyC3c3nu[{Bxd2y7Z3z1eIFucWNiYXPp[E11gXKxc3nu[UBieyC|dXLzeJJifGViYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhU2liPTCwMlAxODRizszNMi=> NXj5bplCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9 NHuyOm5HfW6ldHnvckBie3OjeR?= NILOTVk6OCCvaX7z NWj3b5dWUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDOMZRmem2rbnHsJGdUXC22YXfn[YQhUkGNMzDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KHW|aX7nJGJqd3Srbj3MR{1GWUWGRWDFS2R[TkWZTFWgZZMhe3Wkc4TyZZRmKGGodHXyJFkxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IECuNFAxPiEQvF2u M1r6RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
Sf9 MUnGeY5kfGmxbjDhd5NigQ>? M4[xOlMxKG2rboO= M4DlXmlvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLX\1d4VlKEqDS{GgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy|IIXzbY5oKHCxbInncJV1[W2rYzDhZ4llNXS7cn;zbY5mKGG|IIP1ZpN1emG2ZTDh[pRmeiB|MDDtbY5{KGK7IFXMTXNCNCCNaTC9JFAvODByNzFOwG0v NV;MRW56RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2Olg1QDRpPkKzOlY5PDh2PD;hQi=>
Sf9 MYrGeY5kfGmxbjDhd5NigQ>? NIjpWok{OCCvaX7z NF7uUpRKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD3meZNm\CCMQVuyJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|LXnu[oVkfGWmIGPmPUBk\WyuczD1d4lv\yCyb3z5[4x2fGGvaXOgZYNq\C22eYLvd4lv\SCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCkeTDFUGlUSSxiS3mgQUAxNjByMEeg{txONg>? MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ|Nk[4OFg1RC:jPh?=
Sf9 MUXGeY5kfGmxbjDhd5NigQ>? NGXHbJBKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFfTWE11[WepZXSgTmgyKGSxbXHpckApPzh3IITvNVEzPSlib3[gTmFMOyCneIDy[ZN{\WRiaX6gbY5{\WO2IGPmPUBk\WyuczDifUBGVEmVQTygTWM2OCB;IECuNFAyKM7:TT6= MkjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
Sf9 MX\GeY5kfGmxbjDhd5NigQ>? M3Tz[mlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDoeY1idiCMQVuzJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMECxJO69VS5? M4HzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUC1O|EyLz5{MUGwOVcyOTxxYU6=
Sf9 NYTDWFRbTnWwY4Tpc44h[XO|YYm= MXm5NEBucW6| MUfJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiR2PUMZRi\2enZDDKRWsyKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgeZNqdmdiQnnveIlvNUyFLVXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDUVk1HWkWWIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>? Ml;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
Sf9 MkDSSpVv[3Srb36gZZN{[Xl? M1jaXmlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDoeY1idiCMQVuzJINifGGueYTpZ{Bld22jaX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMECzN{DPxE1w NGXYN2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
Sf9 NXvJVmRWTnWwY4Tpc44h[XO|YYm= M1rwNFkxKG2rboO= MonaTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgTmFMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMEC0JO69VS5? Mn2xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
SF21 NXfWdJFzTnWwY4Tpc44h[XO|YYm= M4PvR|ExKG2rboO= NFXy[ZRKdmirYnn0bY9vKG:oIFrBT|IhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU1[yNUBk\WyuczD1d4lv\yCEaX;0bY4uU0GLRWTET2V[YVSYS1SgZZMhe3Wkc4TyZZRmKGGwZDDbN|NR\2GvbXHdRXRRKGmwY4XiZZRm\CCob4KgNVAhdWmwczDwdolweiC2bzDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiM{CgcYlveyCkeTDUc5Bkd3WwdDDhcoFtgXOrczygTWM2OCB;IECuNFA1KM7:TT6= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2MU[3NEc,OjN3NEG2O|A9N2F-
insect cells NG\2cGtHfW6ldHnvckBie3OjeR?= NIi2OXlKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgToFsOSCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KHW|aX7nJFcxKHWPIFHUVEwhUUN3MDC9JFAvODB4MTFOwG0v NYi4TFFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU3ODVpPkKxNVU2PjB3PD;hQi=>
insect cells MUfGeY5kfGmxbjDhd5NigQ>? MUjJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiSnHrN{BmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEG4JJVOKEGWUDygTWM2OCB;IECuNFA5KM7:TT6= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
T-cells MnTESpVv[3Srb36gZZN{[Xl? MYm3NkBpenN? NGryNHpKdmirYnn0bY9vKG:oIFnMNk1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iVDDj[YxteyCjc4Pld5Nm\CCjczDbN2hefGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjBzMTFOwG0v MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
insect cells MkPFSpVv[3Srb36gZZN{[Xl? NGn2TJNKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgToFsOiCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KHW|aX7nJFIxKHWPIFHUVEwhUUN3MDC9JFAvODF{IN88UU4> M2HzRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
MO7 M3HyR2Z2dmO2aX;uJIF{e2G7 M3TKdmlvcGmkaYTpc44hd2ZiSnHrN{1u\WSrYYTl[EBKVDF3LXnu[JVk\WRiU4TheFUheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJG1QPyClZXzsd{BjgSClZXzsMYJie2WmIHHzd4F6NCCLQ{WwJF0hOC5yMkSg{txONg>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
Ba/F3 MnXqSpVv[3Srb36gZZN{[Xl? NYTJN2dRPjBibXnudy=> MlnHTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiSlHLNUBmgHC{ZYPz[YQhcW5iQnGvSlMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTWGFVPSCyaH;zdIhwenmuYYTpc44h[W[2ZYKgOlAhdWmwczDifUBCdHCqYWPjdoVmdiCjc4PhfUwhUUN3MDC9JFAvODJ4IN88UU4> NEfKT2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
T-cells MXjGeY5kfGmxbjDhd5NigQ>? NF2wemdKdmirYnn0bY9vKG:oIFrBT|MwOSCrbjDoeY1idiCWIHPlcIx{KGW6cILld5NqdmdiQ1SzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNXO2aX31cIF1\WRiU2TBWFViKHCqb4PwbI9zgWyjdHnvckwhUUN3MDC9JFAvODJ6IN88UU4> M3LtcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUSwOlQ5Lz5{M{W0NFY1QDxxYU6=
PBMC NYj4XVVYTnWwY4Tpc44h[XO|YYm= NYm5UXh2UW6qaXLpeIlwdiCLTD23MYlv\GO3ZXSgV3RCXDVicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFCETVOgZ4VtdHNiYomg[oxwfyCleYTvcYV1enluIFnDOVAhRSByLkCzPUDPxE1w MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{N{SyN{c,OjZ7Mke0NlM9N2F-
TF1 NUjXNYRMTnWwY4Tpc44h[XO|YYm= MmXINlAhdWmwcx?= MmDLTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNPi2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMh\m:ubH;3[YQh[nliSVy2JINp[WyuZX7n[UBnd3JiM{CgcYlveyCrbjDwdoV{\W6lZTDv[kB4cG:uZTDicI9w\CxiRVO1NEA:KDBwMESzJO69VS5? NWjpUGdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
TF1 NULvNmxtTnWwY4Tpc44h[XO|YYm= MoPDTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBKVDZvc4TpcZVt[XSnZDDTWGFVOyCyaH;zdIhwenmuYYTpc44h[nliQXzwbIFU[3KnZX6gZZN{[XluIFnOTEA:KDBwMES1JO69VS5? NUO3RY5QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO|I3PTNpPkK2N|czPjV|PD;hQi=>
CTLL MnPDSpVv[3Srb36gZZN{[Xl? NILRcJhKdmirYnn0bY9vKG:oIFrhb|MudWWmaXH0[YQhUUx{LXnu[JVk\WRiU4TheFUheGixc4Doc5J6dGG2aX;uJIlvKG2xdYPlJGNVVExiY3XscJMh[nliY3XscE1j[XOnZDDhd5NigSxiSVO1NEA:KDBwMES4JO69VS5? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
Sf9 MkP4SpVv[3Srb36gZZN{[Xl? NHjkSnc6OCCvaX7z MkPDTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgWHlMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMEWyJO69VS5? MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
TF1 MXjGeY5kfGmxbjDhd5NigQ>? MkOwTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNOi2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjygSWM2OCB;IECuNFU{KM7:TT6= MmDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OUG0NFIoRjJ{NUmxOFAzRC:jPh?=
TF1 NGS0XXdHfW6ldHnvckBie3OjeR?= NYXCdJlVOjBibXnudy=> MXzJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWw3NWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhOjBibXnud{BxemmxcjD0c{BKVDZvaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDNyIITvJFQ2KG2rboOsJGVEPTBiPTCwMlA2OyEQvF2u M3rIO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nkm4NFg1Lz5{Mk[5PFA5PDxxYU6=
TF1 NUTWVmJOTnWwY4Tpc44h[XO|YYm= NGn6R2IzOCCvaX7z NXfjOphEUW6qaXLpeIlwdiCxZjDKRWsyKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgTWw3KGOqYXzs[Y5o\SCob4KgN|AhdWmwczygSWM2OCB;IECuNFU{KM7:TT6= NXzqSW5mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
Ba/F3 NFHZSJNHfW6ldHnvckBie3OjeR?= MWO2NEBucW6| MYDJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCMQVuzJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNE4xPTRizszNMi=> NUTwT25IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
T-cells NVraNmhETnWwY4Tpc44h[XO|YYm= NF\4OJZKdmirYnn0bY9vKG:oIHHscI9o\W6rYzDj[Yxtey2|dHnteYxifGWmIIDyc4xq\mW{YYTpc44hcW5ibX;ub4V6KFRiY3XscJMh[nlibXn4[YQhdHmvcHjvZ5l1\SC{ZXHjeIlwdiCvZYToc4QtKEmFNUCgQUAxNjB3NzFOwG0v Mkf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
CD34+ NIK5fG1HfW6ldHnvckBie3OjeR?= NXTMXpd[UW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKEOGM{SrJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRWDPMY1m\GmjdHXkJINmdGxicILvcIln\XKjdHnvckwhUUN3MDC9JFAvODdzIN88UU4> M2fjbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUK3OFI{Lz5{NkmyO|QzOzxxYU6=
TF1 MlfuSpVv[3Srb36gZZN{[Xl? MlvUTY5pcWKrdHnvckBw\iCLTEStbY5lfWOnZDDwdo9tcW[ncnH0bY9vKG:oIGTGNUBk\WyuczygTWM2OCB;IECuNFgh|ryPLh?= M{PkT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUO0OFU4Lz5zNkmzOFQ2PzxxYU6=
T-cells MXLGeY5kfGmxbjDhd5NigQ>? MYDJcohq[mm2aX;uJI9nKGGubH;n[Y5q[yClZXzsd{1{fGmvdXzheIVlKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gWEBk\WyuczDifUBucXinZDDsfY1xcG:leYTlJJJm[WO2aX;uJI1mfGixZDygTWM2OCB;IECuNFg4KM7:TT6= Ml;jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
TF1 M4PZSWZ2dmO2aX;uJIF{e2G7 M{X4XlIxKG2rboO= NGfMSGxKdmirYnn0bY9vKG:oIFrBT|IhcW5iaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTVCRLXnu[JVk\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiMkCgcYlveyCycnnvdkB1dyCHUF:tbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJJRwKDR3IH3pcpMtKEWFNUCgQUAxNjB7MzFOwG0v MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ7OEC4OEc,OjJ4OUiwPFQ9N2F-
TF1 MofqSpVv[3Srb36gZZN{[Xl? NXLPPFJFOjBibXnudy=> NEn1d3JKdmirYnn0bY9vKG:oIFrBT|IhcW5iaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTVCRLXnu[JVk\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiMkCgcYlveyCob3zsc5dm\CCkeTDJUFYh[2ijbHzlcodmKG[xcjCzNEBucW6|LDDFR|UxKD1iMD6wPVMh|ryPLh?= M2\2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkW5NlE1Lz5{M{[1PVIyPDxxYU6=
PBMC MkPBSpVv[3Srb36gZZN{[Xl? NIf1VJZKdmirYnn0bY9vKG:oIFrBT|EhcW5iaIXtZY4hWEKPQzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOLU[tbY5lfWOnZDDNR3AyKHOnY4LleIlwdixiSVO1NEA:KDBwMEm1JO69VS5? MkTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7Mke0NlMoRjJ4OUK3OFI{RC:jPh?=
TF1 NETBbJdHfW6ldHnvckBie3OjeR?= Mm\SNkBpenN? M3HaZ2lvcGmkaYTpc44hd2ZiSlHLNkBqdiCJTVPTSk1{fGmvdXzheIVlKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSCJTVPTSkB{fGmvdXzheIlwdiCob4KgOVAhdWmwczDifUBHSUOVIILlZYRmeiCjbnHsfZNqeyxiSVO1NEA:KDBwMEm1JO69VS5? MlrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{CzOVkoRjJ5MUOwN|U6RC:jPh?=
TF1 Mn;sSpVv[3Srb36gZZN{[Xl? NGC4NmNKdmirYnn0bY9vKG:oIFrBT|IhcW5iRWDPMZN1cW23bHH0[YQhcHWvYX6gWGYyKGOnbHzzJIV5eHKnc4Ppcoche3SjYnz5JIlvfGWpcnH0[YQh[mW2YT3sZYN1[W2jc3WgdoVxd3K2ZYKg[4Vv\SC3bnTldkBkd262cn;sJI9nKFOWQWS1JJJme3CxboPlJIVt\W2nboTzJIlvKGmwdHXy[oVzd25icnXneYxifG:{eTDmZYN1d3JiMTDn[Y5mKHC{b33veIVzKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNVA4KM7:TT6= NYnWV2JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOVYyOzZpPkK5NVU3OTN4PD;hQi=>
Sf9 MV7GeY5kfGmxbjDhd5NigQ>? NEXnUFdKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgbJVu[W5iSlHLNUBk[XSjbIn0bYMh\G:vYXnuJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYomgSWxKW0FuIFnDOVAhRSByLkGxJO69VS5? NIqyPXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
T-cells NFryZWRHfW6ldHnvckBie3OjeR?= NHnEUGZKdmirYnn0bY9vKG:oIHHscI9o\W6rYzDj[Yxtey2|dHnteYxifGWmIIDyc4xq\mW{YYTpc44hcW5ibX;1d4UhXCClZXzsd{BjgSCvaYjl[EBtgW2yaH;jfZRmKHKnYXP0bY9vKG2ndHjv[EwhUUN3MDC9JFAvOTF3IN88UU4> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
ME180 MojpSpVv[3Srb36gZZN{[Xl? Mlv0TY5pcWKrdHnvckBw\iCMQVuxJIlvKEmONj3zeIlufWyjdHXkJIh2dWGwIF3FNVgxKGOnbHzzJIV5eHKnc4Ppcoche3SjYnz5JIlvfGWpcnH0[YQh[mW2YT3sZYN1[W2jc3WgdoVxd3K2ZYKg[4Vv\SC3bnTldkBkd262cn;sJI9nKHOrcz3pcoR2[2mkbHWg[YxmdWWwdDDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjF{NDFOwG0v M1LYWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUW2NVM3Lz5{OUG1OlE{PjxxYU6=
CTLL-2 MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MlmyO|IhcHK| NU\UTpo3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBKVC1{LYP0bY12dGG2ZXSgcY92e2ViQ2TMUE0zKGOnbHzzJIV5eHKnc4PpcochUkGNMT;KRWs{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvOTN{IN88UU4> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
HT2 M1XkOmZ2dmO2aX;uJIF{e2G7 NV31S4dXUW6qaXLpeIlwdiCxZjDKRWs{KGmwIH3veZNmKEiWMjDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iClZXzsJIdzd3e2aDygTWM2OCB;IECuNVU3KM7:TT6= NXHNUG9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|EyQDBpPkK3O|cyOThyPD;hQi=>
DND/L12 NH:3dWdHfW6ldHnvckBie3OjeR?= MVGzNEBucW6| M4rncmlvcGmkaYTpc44hd2ZiSlHLN{BqdiCqdX3hckBFVkRxTEGyJINmdGy|IHHmeIVzKDNyIH3pcpMh[nlibIXjbYZmemG|ZTDhd5NigSCrbjDwdoV{\W6lZTDv[kBpfW2jbjDz[ZJ2dSCjbHL1cYlvNCCLQ{mwJF0hOC5zNjFOwG0v NYnCc41VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
T-cells Ml3USpVv[3Srb36gZZN{[Xl? Ml2zTY5pcWKrdHnvckBw\iCMQVuyM|EhcW5iaIXtZY4hXCClZXzsd{BmgHC{ZYPzbY5oKEOGMzDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnGUodidW2jLYP0bY12dGG2ZXSgV3RCXDFicHjvd5Bpd3K7bHH0bY9vNCCLQ{WwJF0hOC5zNzFOwG0v MoS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEC2OFgoRjJ|NUSwOlQ5RC:jPh?=
insect NVmzXmtnTnWwY4Tpc44h[XO|YYm= MoDsTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIGT5b|Ih\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{B2e2mwZzCzOUB2VSCDVGCsJGlEPTBiPTCwMlE4PiEQvF2u NH32ZYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
Ba/F3 M{jXeWZ2dmO2aX;uJIF{e2G7 MlW2OlAhdWmwcx?= M{f3emlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFrBT|Ih\XiycnXzd4VlKGmwIFLhM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gV3RCXDVicHjvd5Bpd3K7bHH0bY9vKGGodHXyJFYxKG2rboOgZpkhSWyyaHHTZ5Jm\W5iYYPzZZktKEmFNUCgQUAxNjJ4NTFOwG0v NXuyTmdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
TF1 M1zndGZ2dmO2aX;uJIF{e2G7 MYXJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINmdGxiZ4Lve5RpNCCLQ{WwJF0hOC5{N{WxJO69VS5? M2TKeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{exNVgxLz5{N{e3NVE5ODxxYU6=
CD34+ M2nhNmZ2dmO2aX;uJIF{e2G7 M3LMS2lvcGmkaYTpc44hd2ZiSlHLNkBpd22xZHnt[ZIhcW5iaIXtZY4hS0R|NDugZ4VtdHNic4Dpb4VlKGmwdH:gbJVu[W5id3jvcIUh[myxb3SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDFVG8ucW6mdXPl[EBUXEGWLUWgdIhwe3Cqb4L5cIF1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiNEWgcYlveyCob3zsc5dm\CCkeTDFVG8h[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNVUhdWmwczDifUBHSUOVIHHuZYx6e2m|LDDJR|UxKD1iMD6zNFIh|ryPLh?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{WzN{c,OjR2MUe1N|M9N2F-
HUO3 NGPPS3JHfW6ldHnvckBie3OjeR?= MWK0JIRigXN? M3;vNmlvcGmkaYTpc44hd2ZiaIXtZY4hT01vQ2PGMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCrbjDoeY1idiCKVV:zJINmdGy|IHHzd4V{e2WmIHHzJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC0JIRigXNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwM{K0JO69VS5? M37ycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
HU03 NUHEeo1KTnWwY4Tpc44h[XO|YYm= Mn;XO|IhcHK| NWq0WYFmUW6qaXLpeIlwdiCxZjDHUU1EW0ZvaX7keYNm\CCqdX3hckBJXTB|IHPlcIx{KHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGuzTH11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwM{K0JO69VS5? MmnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzMEW3NVEoRjJzMUC1O|EyRC:jPh?=
BAF3 NEfPU5JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NW\ZeJpnPzJiaILz M3rKcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDlfJBz\XO|aX7nJHRGVC2MQVuzJItqdmG|ZTDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkW3JO69VS5? NH7OeI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe2NlI{QCd-MUm3OlIzOzh:L3G+
T-cells M1S0UGZ2dmO2aX;uJIF{e2G7 MnvMN{Bl[Xm| M4C1O2lvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;mJGlNOi2jY4TpeoF1\WRiYX7kJGNFOyCjbnSgR2QzQCCjboTpZo9lgS2|dHnteYxifGWmIH3veZNmKEOGND3wc5NqfGm4ZTDUJINmdGy|IHHmeIVzKDNiZHH5d{BjgSC[VGSgZZN{[XluIFnDOVAhRSByLk[zJO69VS5? M2r0WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNE[wPFQzLz5|MES2NFg1OjxxYU6=
NK92 M1G3[2Z2dmO2aX;uJIF{e2G7 NUfxZVg{OjBibXnudy=> MV7Jcohq[mm2aX;uJI9nKFS\S{KgbY4hcHWvYX6gUms6OiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNOTJvaX7keYNm\CCVVFHUOEBxcG:|cHjvdplt[XSrb36gbY5kfWKjdHXkJIZweiB{MDDtbY5{KG[xbHzve4VlKGK7IFnMNVIh[2ijbHzlcodmKG[xcjC0OUBucW6|LDDFR|UxKD1iMD63NUDPxE1w NYK4W3hMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
TF1 M1XuRWZ2dmO2aX;uJIF{e2G7 NUnRSW5jUW6qaXLpeIlwdiCxZjDJUFMucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJHRHOSClZXzsd{whUUN3MDC9JFAvQCEQvF2u M4DNV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUO0OFU4Lz5zNkmzOFQ2PzxxYU6=
UT7 MVHGeY5kfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWXQ4KGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGVRVy2|dHnteYxifGWmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBjgSCDbIDoZXNkemWnbjDhd5NigSxiSV7IJF0hOS5zMjFOwG0v NEHvbIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO3NlY2Oyd-Mk[zO|I3PTN:L3G+
Ba/F3 NEnadWVHfW6ldHnvckBie3OjeR?= MYK2NEBucW6| MVfJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCWWVuyJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNU4zKM7:TT6= M2X3fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
T-cells MXrGeY5kfGmxbjDhd5NigQ>? M1nYWlczKGi{cx?= NWXDRVBoUW6qaXLpeIlwdiCxZjDKRWs{KGmwIILheEB{eGynbn;jfZRq[yCWIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBKVC1{LXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSBzLkKg{txONg>? NFLOb2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEGzPVU4PSd-M{CxN|k2PzV:L3G+
SZ4 MWDGeY5kfGmxbjDhd5NigQ>? M1j6VGlvcGmkaYTpc44hd2ZiSlHLN{BqdiCqdX3hckBUYjRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGlNOi2|dHnteYxifGWmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBxemWrbnP1ZoF1\WRiZn;yJFEhcHJiZn;scI94\WRiYomgTWwzKHO2aX31cIF1cW:wIHHu[EBu\WG|dYLl[EBi\nSncjCxOUBucW6|IHL5JG1UTCCjc4PhfUwhUUN3MDC9JFEvOjFizszNMi=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR4MEi0Nkc,OzB2NkC4OFI9N2F-
BAF3 MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MWK3NkBpenN? NHnXNFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOg[ZhxemW|c3nu[{BVTUxvSlHLNkBscW6jc3WgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxKD1iMT61O|Qh|ryPLh?= NUHwTHVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzhpPkG5O|YzOjN6PD;hQi=>
HEL M3GxO2Z2dmO2aX;uJIF{e2G7 NIrtVHIyKGi{ Mn[2TY5pcWKrdHnvckBw\iCMQVuyJHY3OTeIIH31eIFvfCCrbjDoeY1idiCKRVygZ4VtdHNiYX\0[ZIhOSCqcjygTWM2OCB;IESuO|I1KM7:TT6= NF3HcnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3NVE5OCd-Mke3O|EyQDB:L3G+
Jurkat MXzGeY5kfGmxbjDhd5NigQ>? NV3vVYd2OjRiaILz MVHJcohq[mm2aX;uJI9nKGGwdHmtR2Q{N2GwdHmtR2QzQC2rbnT1Z4VlKEmOMjDwdo9lfWO2aX;uJIlvKGi3bXHuJGp2emujdDDj[YxteyCjZoTldkAzPCCqcoOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IEeuPFQh|ryPLh?= NFfEbXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
YT NFLiToVHfW6ldHnvckBie3OjeR?= NVzqNXRCOzBibnevcYw> NWfLc2xjUW6qaXLpeIlwdiCxZjDJUFIucW6mdXPl[EBLSUt|IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiC\VDDj[YxteyCjdDCzNEBv\y:vbDDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrcx?= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
YT NXW0VoV5TnWwY4Tpc44h[XO|YYm= NILQOZY{OCCwZz;tcC=> M{fuR2lvcGmkaYTpc44hd2ZiSVyyMYlv\HWlZXSgV3RCXDWDIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiC\VDDj[YxteyCjdDCzNEBv\y:vbDDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrcx?= M{X1[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
YT MkjSSpVv[3Srb36gZZN{[Xl? M1zmVFMxKG6pL33s MnPhTY5pcWKrdHnvckBw\iCLTEKtbY5lfWOnZDDTWGFVPUJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFmWIHPlcIx{KGG2IEOwJI5oN22uIHL5JIludXWwb3Lsc5R1cW6pIHHuZYx6e2m| NF;uZnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
NK-cells NHvzVndKdW23bn;zeZBxemW|c3n2[UBie3OjeR?= NYn3eI5uOSC2bzC1JI1oN2up NHPTXGQ1KHenZXvz M1SwdmludXWwb4P1dJBz\XO|aY\lJIFkfGm4aYT5JIlvKG6jaY\lJIN6dm:vb3zneZMhdW:wa3X5JIF{e2W|c3XkJIF{KGWoZnXjeEBwdiCFREOtR2QyPitiTlugZ4VtdHNiYYSgNUB1dyB3IH3nM4toNCCybzDmc5IhPCC5ZXXrdy=> NGnsc|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
T-cells MVLGeY5kfGmxbjDhd5NigQ>? NVzPbmcxPSC2bzC1NFAhdk1? MnLTNUBpeg>? M3:wOWlvcGmkaYTpc44hd2ZiSVyyMYlv\HWlZXSgV5RifDVicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEOGNDugWEBk\WyuczDheEA2KHSxIEWwNEBvVSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfA>? M3HTe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEWzO|U3Lz5zOUC1N|c2PjxxYU6=
SUM149PT NV7sNpI4TnWwY4Tpc44h[XO|YYm= NVHRWJVvOyC3TR?= NXvKZmJoOTZiaILz NVTxSYtRUW6mdXP0bY9vKG:oIGDUVG43KGmwIHj1cYFvKFOXTUG0PXBVKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEOgeW0h[W[2ZYKgNVYhcHK|IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm|aYOgbY4heHKnc3XuZ4Uhd2ZicHXyeoFv[WSjdHW= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5OEGxNkc,OjR7N{ixNVI9N2F-
Hs578T M3fpOGZ2dmO2aX;uJIF{e2G7 MY[zJJVO NEnjZoMyPiCqcoO= MoW3TY5lfWO2aX;uJI9nKFCWUF62JIlvKGi3bXHuJGh{PTd6VDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEA{KHWPIHHmeIVzKDF4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{KGmwIIDy[ZNmdmOnIH;mJJBmen[jbnHkZZRm MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5OEGxNkc,OjR7N{ixNVI9N2F-
T-cells MmPiSpVv[3Srb36gZZN{[Xl? M3K2[FUxKHSxIEOwNEBvVQ>? NWrSbpRoOSCqch?= NUXnWmpjUW6qaXLpeIlwdiCxZjDKRWsyN0qDS{OgbY4hcHWvYX6gR2Q1KHCxc3n0bZZmKFRiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVDRvc4TpcZVt[XSnZDDTWGFVPiCyaH;zdIhwenmuYYTpc44h[XRiNUCgeI8hOzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE01KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= Mo\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
T-cells M1zS[mZ2dmO2aX;uJIF{e2G7 NITWU|g2OCC2bzCzNFAhdk1? MYixJIhz NFXOToJKdmirYnn0bY9vKG:oIFrBT|EwUkGNMzDpckBpfW2jbjDDSFQheG:|aYTpeoUhXCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNOi2|dHnteYxifGWmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBifCCWeYKtOlk2KHKnc3nkeYUh[XRiNUCgeI8hOzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE0zKHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= MkDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
T-cells MWHGeY5kfGmxbjDhd5NigQ>? MnPtQlMxOCCwTR?= M1rVO|EhcHJ? NUPtVnJPUW6qaXLpeIlwdiCxZjDKRWsyN0qDS{KvWHlMOiCrbjDoeY1idiCFRESgdI9{cXSrdnWgWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMOk1{fGmvdXzheIVlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEA,OzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE03KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= NVT5e4pFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVIxPjhpPkK5PFUzODZ6PD;hQi=>
TALL-1 M33Td2Z2dmO2aX;uJIF{e2G7 Mny4NUB2VQ>? MVSzJIhzew>? MlfpTY5pcWKrdHnvckBw\iCMQVuzJIlvKGi3bXHuJHRCVExvMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOLUKgbY5lfWOnZDDTWGFVPSCyaH;zdIhwenmuYYTpc44h[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFMhcHK|IH\vcIxwf2WmIHL5JGlNNTJiaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdITpcoc> M{jh[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BA/F3 M1HlNmZ2dmO2aX;uJIF{e2G7 M4nH[lMxOCCwTR?= M1LxdVMhcHK| NVnCXnhEUW6qaXLpeIlwdiCxZjDKRWs{KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCVVFHUOUBxcG:|cHjvdplt[XSrb36gZZQhOzByIH7NJIFnfGW{IEOgbJJ{KGK7IHntcZVvd2Kub4T0bY5oKGGwYXz5d4l{ MnvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
OCL-AML5 M{nwVmZ2dmO2aX;uJIF{e2G7 NX\QZY9xOSC3TR?= NWHZe4NiOyCqcoO= MUPJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gU2NNNUGPTEWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCJTT3DV2YhcW6mdXPl[EBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KEePLVPTSkBqdmS3Y4Tpc44hdWWjc4Xy[YQh[W[2ZYKgN|AhdWmwczDifUBqdW23bn;icI91fGmwZx?= MoKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
BA/F3 M{K1bmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M4PKRVczKGi{cx?= MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegWGVNNUqDS{OgZYZ1\XJiN{KgbJJ{KGK7IHPlcIwhfGm2ZYKg[4xwKGG|c3H5 M1LkVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BA/F3 NWTzPIZETnWwY4Tpc44h[XO|YYm= M1S1dlEhfU1? NUXk[FFoOyCqcoO= MXzJcohq[mm2aX;uJI9nKEqDS{OgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hdW:3c3WgRmEwTjNiY3XscJMh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFMhcHK|IH\vcIxwf2WmIHL5JJB2dGymb4fuJJdqfGhic4Ty[ZB1[X[rZHnuJIJm[WS|IHL5JIludXWwb3Lsc5R1cW6pIHHuZYx6e2m| MmPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
Huh7 NY[5O29GTnWwY4Tpc44h[XO|YYm= M{PSOVExKHWP NXe2WYN1OzBibXnudy=> NUXEcYpJUW6qaXLpeIlwdiCxZjDUfYszKGmwIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEmITnHsdIhiPS2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDwdoUucW6ldXLheIVlKG[xcjCzNEBucW6|IHLl[o9z\SCLRl7hcJBp[TVic4TpcZVt[XSrb36g[o9zKDNyIH3pcpMhdWmwczDifUBqdW23bn;icI91fGmwZx?= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1PUc,OjZ{M{GxOVk9N2F-
Huh7 NIfyZo1HfW6ldHnvckBie3OjeR?= M3\QO|ExKHWP MoDuN|AhdWmwcx?= M1TYbmlvcGmkaYTpc44hd2ZiVInrNkBqdiCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBj[XOjbDDs[ZZmdCCVVFHUN{BxcG:|cHjvdplt[XSrb36gZZQhOTBidV2gZYZ1\XJiM{CgcYlveyCkeTDpcY12dm:kbH;0eIlv\w>? NGnHPHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE2QSd-Mk[yN|EyPTl:L3G+
Huh7 MV3GeY5kfGmxbjDhd5NigQ>? MmrzNUB2VQ>? M1\NRVMxKG2rboO= M{f5UGlvcGmkaYTpc44hd2ZiVInrNkBqdiCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBKTk6jbIDoZVUucW6mdXPl[EBUXEGWMzDwbI9{eGixconsZZRqd25iYYSgNUB2VSCycnWtbY5kfWKjdHXkJIZweiB|MDDtbY5{KGKnZn;y[UBKTk6jbIDoZVUhe3SrbYXsZZRqd25iZn;yJFMxKG2rboOgcYlveyCkeTDpcY12dm:kbH;0eIlv\w>? M1fOT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVU6Lz5{NkKzNVE2QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
JAK3 / STAT5 / p-STAT5 ; 

PubMed: 27732937     


The following cell lines: EBV-negative B cell line (BJAB), EBV-transformed lymphoblastoid cell line (LCL), EBV-negative T cell lines (Jurkat and MOLT4), EBV-positive T cell lines (SNT15 and SNT16), EBV-negative NK cell line (KHYG1), and EBV-positive NK cell lines (KAI3 and SNK6), were treated without (−) or with (+) 1 μM tofacitinib for 24 h and cell lysates were then immunoblotted for the indicated proteins.

LMP1 / EBNA1 / BZLF1 ; 

PubMed: 27732937     


SNT13, SNT15, SNT16, KAI3 and SNK6 cell lines were treated with 5 μM tofacitinib for 48 h, and cell lysates were immunoblotted for LMP1, EBNA1 and BZLF1. Actin was blotted as a loading control.

JAK3 / p-JAK3 / STAT3 ; 

PubMed: 26082451     


CTCL cell lines were subjected to western blot (tofacitinib 10, 100, 200 nM) (G) after 48 hours of treatment.

27732937 26082451
Growth inhibition assay
Cell number ; 

PubMed: 27732937     


BJAB, LCL, Jurkat, SNT15, KHYG1 and KAI3 cells were treated with the indicated concentrations of tofacitinib, and viable cells were counted at the indicated times using the trypan blue exclusion test. Values are means ± SE of the results from triplicate experiments. *P < 0.05 as compared with DMSO-treated cells.

27732937
In vivo In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ~60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). [1] Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrates dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice is observed with CP-690550 monotherapy (10–30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). [2]

Protocol

Kinase Assay:

[1]

- Collapse

JAK3 Kinase Assay:

A fragment encoding the catalytic domain of human JAK3 (785aa to 1125aa, JH1 catalytic domain) is amplified by PCR from the full length cDNA and cloned into the EcoRI site of the baculovirus transfer vector pVL1393. Recombinant baculovirus is used to infect Sf9 (Spodoptera frugipedra) cells and recombinant GSTJAK3 fusion protein is isolated on glutathione sepharose. The fusion protein is eluted with reduced glutathione and stored in buffer containing 50 mM Tris, pH 7.5, 10 mM DTT and 10% glycerol. JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1) (100 ug/mL). The plates are washed and recombinant JAK3 JH1:GST (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes, after which HRP-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine). Other kinases (Table 1) are produced in E. coli or in insect cells, depending upon what is found to be optimal for the given kinase. The catalytic activity of tyrosine kinases is easured using the aftorementioned ELISA, whereas serine/threonine kinases are assayed using radioactive enzyme assays.
Cell Research:

[1]

- Collapse
  • Cell lines: Human T blasts cell
  • Concentrations: 0-4000 nM
  • Incubation Time: 4 days
  • Method:

    To measure IL-2-dependent proliferation, isolated lymphocytes are resuspended to a cell density of 1-2 × 106/mL in complete RPMI medium (RPMI 1640 containing 10% (w/v) fetal calf serum (FCS), 1%(w/v) penicillin and treptomycin).Phytohemagluttinin (PHA) is added to a final concentration of 10mg/mL, and the culture incubated for 3 days at 37 °C in a humidified 5% (v/v) CO2 incubator to upregulate IL-2R and JAK3 expression. IL-2 (200U/mL), with or without CP-690,550 is then added and the cells are incubated for 72 hours at 37 °C in a humidified 5% (v/v) CO2 incubator, after which 50 mL of 3H-thymidine (5mCi/mL) is added. The plates are incubated for an additional 18 hours, harvested with a 96-well harvester, and counted on a scintillation counter. HUO3 cells are maintained in culture with granulocyte-macrophage colony stimulating factor and human foreskin fibroblasts are maintained in culture with 10% fetal calf serum. CP-690550 is added to freshly plated cells and cultured for 4 days. 3Hthymidine is added during the last 18 hours of the culture period.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: DBA/2 and C57/BL6 mice
  • Dosages: 0-136 ng/mL
  • Administration: Administered via osmotic minipump infusion
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 62 mg/mL warmed (198.48 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 312.37
Formula

C16H20N6O

CAS No. 477600-75-2
Storage powder
in solvent
Synonyms Tasocitinib
Smiles CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04496960 Recruiting Drug: tofacitinib|Other: Placebo Sjogren''s Syndrome National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) May 18 2021 Phase 1|Phase 2
NCT04768504 Not yet recruiting Drug: Tofacitinib 10 mg Immune-Mediated Colitis Khashayar Esfahani|Sir Mortimer B. Davis - Jewish General Hospital April 2021 Phase 2
NCT04624230 Recruiting Drug: tofacitinib Ulcerative Colitis Pfizer April 30 2021 Phase 3
NCT04424303 Recruiting Drug: Tofacitinib Ulcerative Colitis Pfizer December 7 2020 --
NCT04468425 Recruiting Drug: Tofacitinib Citrate Healthy Subjects TWi Biotechnology Inc. October 14 2020 Phase 1
NCT04576000 Recruiting Drug: Tofacitinib Ulcerative Colitis Alimentiv Inc. August 25 2020 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was just wondering what the main differences between S2789 and S5001?

  • Answer:

    S2789(Tofacitinib (CP-690550)) is the base form of S5001 (Tofacitinib (CP-690550) Citrate). The biological activity of these two compounds are same. The S5001 (Tofacitinib (CP-690550) Citrate) is more suitable for oral administration.

JAK Signaling Pathway Map

JAK Inhibitors with Unique Features

Related JAK Products

Tags: buy Tofacitinib (CP-690550) | Tofacitinib (CP-690550) supplier | purchase Tofacitinib (CP-690550) | Tofacitinib (CP-690550) cost | Tofacitinib (CP-690550) manufacturer | order Tofacitinib (CP-690550) | Tofacitinib (CP-690550) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID